Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
FDA Office of Orphan Products Development Charles Drew University of Medicine and Science |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
ClinicalTrials.gov Identifier: | NCT00004400 |
OBJECTIVES: I. Determine whether physiologic testosterone replacement can increase fat-free mass, therefore contributing to weight maintenance, improved muscle function, and quality of life in HIV-infected women. II. Examine the mechanism of testosterone-induced increase in fat-free mass.
Condition | Intervention | Phase |
---|---|---|
HIV Infections Cachexia |
Drug: testosterone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study |
Estimated Enrollment: | 56 |
Study Start Date: | April 1997 |
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are randomized to one of three arms.
Arm I: Patients receive two placebo transdermal patches applied twice a week (every 3-4 days).
Arm II: Patients receive one testosterone transdermal patch and one placebo transdermal patch applied twice a week (every 3-4 days).
Arm III: Patients receive two testosterone transdermal patches applied twice a week (every 3-4 days).
Patients receive 12 weeks of treatment in the absence of adverse reaction or health deterioration. Patients are followed on day 1, every 2 weeks during treatment, and at the end of the recovery period. Quality of life is assessed before treatment begins and at weeks 6 and 12.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
United States, California | |
Charles R. Drew University of Medicine and Science | Recruiting |
Los Angeles, California, United States, 90059 | |
Contact: Shalender Bhasin 213-563-9353 | |
Los Angeles County Harbor-UCLA Medical Center | Recruiting |
Torrance, California, United States, 90509 | |
Contact: G. Beall 310-222-2444 | |
United States, Missouri | |
Washington University School of Medicine | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
Contact: K. Yarashaski 314-362-9700 |
Study Chair: | Shalender Bhasin | Charles Drew University of Medicine and Science |
Study ID Numbers: | 199/13251, CDUMS-FDR001397 |
Study First Received: | October 18, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00004400 History of Changes |
Health Authority: | United States: Federal Government |
cachexia disease-related problem/condition human immunodeficiency virus infection immunologic disorders and infectious disorders |
nutrition quality of life rare disease viral infection |
Sexually Transmitted Diseases, Viral Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Cachexia Quality of Life Hormones Body Weight Signs and Symptoms Weight Loss Body Weight Changes Retroviridae Infections Antineoplastic Agents, Hormonal Acquired Immunodeficiency Syndrome |
Rare Diseases Emaciation Methyltestosterone Immunologic Deficiency Syndromes Testosterone 17 beta-cypionate Virus Diseases Testosterone Anabolic Agents HIV Seropositivity HIV Infections Sexually Transmitted Diseases Androgens |
Sexually Transmitted Diseases, Viral Slow Virus Diseases Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Cachexia Infection Hormones Body Weight Signs and Symptoms Therapeutic Uses Weight Loss Body Weight Changes Retroviridae Infections RNA Virus Infections |
Antineoplastic Agents, Hormonal Immune System Diseases Acquired Immunodeficiency Syndrome Emaciation Methyltestosterone Pharmacologic Actions Immunologic Deficiency Syndromes Testosterone 17 beta-cypionate Virus Diseases Anabolic Agents Testosterone HIV Infections Sexually Transmitted Diseases Lentivirus Infections Androgens |